Evidence map›Paper›PMID 35393360›Full record

ArticleStroke and vascular neurology2022

Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial.

Yuesong Pan, Xia Meng, Weiqi Chen, Jing Jing, Jinxi Lin, Yong Jiang, S Claiborne Johnston, Philip M Bath, Qiang Dong, An-Ding Xu and 2 more

Erratum issued Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Stroke and vascular neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03871517 (INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03871517 phase4completednot on this map

INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE

TypeinterventionalSponsorBeijing Tiantan HospitalRan2019 to 2022Enrolled5,438ConditionsIschemic Stroke, Indobufen, AspirinArmsIndobufen, Aspirin
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Yuesong Pan *Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0003-3082-6789
Xia Meng *Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Weiqi ChenDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-2551-9314
Jing JingDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0001-9822-5758
Jinxi LinDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Yong JiangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
S Claiborne JohnstonDell Medical School, The University of Texas System, Austin, Texas, USA.ORCID 0000-0002-2912-0714
Philip M BathStroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK.
Qiang DongDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
An-Ding XuDepartment of Neurology, The First Affiliated Hospital of Jinan University, Guangzhou, China.ORCID 0000-0003-3154-0985
Hao LiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-8591-4105
Yongjun WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China yongjunwang@ncrcnd.org.cn.
Capital Medical University · CNFirst Affiliated Hospital of Jinan University · CNFudan University · CNThe University of Texas System · USUniversity of Nottingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIndobufen can reversibly inhibit platelet aggregation and showed to be effective in the treatment of ischaemic heart and peripheral vascular diseases. However, it is unclear whether indobufen is an alternative antiplatelet agent for treatment of patients with ischaemic stroke.

aimTo test whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke.

designThe Indobufen vs Aspirin in Acute Ischaemic Stroke (INSURE) is a randomised, double-blind, double-dummy, positive drug control, non-inferior multicentre clinical trial conducted in 200 hospitals in China. Participants will be randomised at a 1:1 ratio to receive either 100 mg indofufen two times daily or 100 mg aspirin once daily within 72 hours of the onset of symptoms from day 1 to 3 months. STUDY OUTCOMES: The primary efficacy outcome is a new stroke (ischaemic or haemorrhagic) within 3 months and the primary safety outcome is a severe or moderate bleeding event within 3 months. DISCUSSION: The INSURE trial will evaluate whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke. TRIAL REGISTRATION NUMBER: NCT03871517.

Indexed as

Brain IschemiaIschemic StrokeStrokeAspirinHemorrhageHumansIsoindolesMulticenter Studies as TopicPhenylbutyratesPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicTreatment OutcomeAspirinindobufenIsoindolesPhenylbutyratesPlatelet Aggregation Inhibitorscerebral infarctionclinical trialstroke

Identifiers

PMID35393360
PMCPMC9614137
OpenAlexW4225746969

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.